Presentation MedCap Q3 2021

Q3 Presentation 2021

We create value and contribute to improved quality of life in Life Science

2

MedCap | An active investor in Life Science companies

MedTech Business Area

Sales by Segment (MSEK)		Geographies
	5%
35%	21%		Sweden
885	53%		Nordic
	Europe
65%	21%		RoW

Specialty Pharma Business Area

Employees

358

Listed on Stockholm

Nasdaq Mid Cap

MedTech Specialty Pharma

3

Highlights Q3

• Sales growth
• EBITDA increased by 24% excluding one- time effects of 11.8 mSEK this quarter and 4.8 mSEK last year
• All companies in the MedTech segment contributed to sales and EBITDA growth
• Strong margin (20% EBITDA-margin (17%) after excluding one-time effects)
• One acquisition supports growth

	Q3 2021
Net Sales	202.3 +15%
(MSEK)

EBITDA	49.5	+41%
(MSEK)

EBITDA-	24% +4.4 ppt
margin

4

Sales and EBITDA by quarter

+15%

Net sales per quarter (MSEK)

250								200			211	206	209		227	223	233	202
200				183			188	186		175
			173	166	160
139	152
150	120
100
50
0	Q1	Q2	Q3	Q1	*	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
	Q2
	17/18			18				19				20

EBITDA per quarter (MSEK)							+41%
60
50					41			41		50	46	50
					36	38			41
40						35
							27	31
30			22
			20
20	14	17	19	17
12
10
0	Q1 Q2 Q3	Q1 Q2*	Q3	Q4 Q1	Q2	Q3 Q4	Q1 Q2 Q3 Q4	Q1 Q2 Q3
	17/18		18		19			20

Q3 YTD R12

Net Sales

growth +15% +12% +10%

EBITDA

growth +41% +26% +19%

EBITDA-

margin 24% 21% 21%

Acquisitions that impact quarter comparison

• MedCap acquisition: Multi-ply (from 29 Oct 2020)
• One-timeeffects of 11.8 mSEK in Q3 2021 and 4.8 mSEK in Q3 2020

• Q3 2017/18: two months
• IFRS16 incl. from Q1 2019